Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Core Scientific (CORZ) EBT Margin (2021 - 2025)

Core Scientific's EBT Margin history spans 5 years, with the latest figure at 270.87% for Q4 2025.

  • For Q4 2025, EBT Margin rose 55021.0% year-over-year to 270.87%; the TTM value through Dec 2025 reached 91.11%, up 16622.0%, while the annual FY2025 figure was 90.29%, 16705.0% up from the prior year.
  • EBT Margin for Q4 2025 was 270.87% at Core Scientific, up from 180.68% in the prior quarter.
  • Across five years, EBT Margin topped out at 724.87% in Q1 2025 and bottomed at 1191.23% in Q2 2025.
  • The 5-year median for EBT Margin is 86.99% (2023), against an average of 156.5%.
  • The largest YoY upside for EBT Margin was 60725bps in 2025 against a maximum downside of -62090bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 25.5% in 2021, then plummeted by -1576bps to 376.36% in 2022, then skyrocketed by 63bps to 137.64% in 2023, then crashed by -103bps to 279.34% in 2024, then soared by 197bps to 270.87% in 2025.
  • Per Business Quant, the three most recent readings for CORZ's EBT Margin are 270.87% (Q4 2025), 180.68% (Q3 2025), and 1191.23% (Q2 2025).